These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35121247)

  • 1. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease.
    AbdelRazek MA; Casasola M; Mollashahi R; Brodski A; Morin S; Augustynowicz A; Jassim S; Matiello M; Sloane J
    Mult Scler Relat Disord; 2022 Mar; 59():103505. PubMed ID: 35121247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.
    Toorop AA; van Lierop ZYGJ; Strijbis EMM; Teunissen CE; Barkhof F; Uitdehaag BMJ; van Kempen ZLE; Killestein J
    Mult Scler Relat Disord; 2022 Jan; 57():103364. PubMed ID: 35158470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.
    Capasso N; Nozzolillo A; Scalia G; Lanzillo R; Carotenuto A; De Angelis M; Petruzzo M; Saccà F; Russo CV; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2021 Apr; 49():102802. PubMed ID: 33556652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropaenia complications from Ocrelizumab and Rituximab treatment.
    Pang V; Seery N; Wesselingh R; Yeh W; Zhong M; Tan T; Dwyer C; Nesbitt C; Rath L; Perera D; Bridge F; Skibina O; Bosco JJ; Jokubaitis V; Marriott M; Butkueven H; Van Der Walt A; Massey J; Sutton I; Monif M
    Mult Scler Relat Disord; 2024 Jan; 81():105147. PubMed ID: 38043368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
    D'Amico E; Zanghì A; Chisari CG; Fermo SL; Toscano S; Arena S; Patti F; Zappia M
    Mult Scler Relat Disord; 2019 Jan; 27():324-326. PubMed ID: 30471585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
    Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
    Rodriguez-Mogeda C; van Lierop ZYGJ; van der Pol SMA; Coenen L; Hogenboom L; Kamermans A; Rodriguez E; van Horssen J; van Kempen ZLE; Uitdehaag BMJ; Teunissen CE; Witte ME; Killestein J; de Vries HE
    J Neuroinflammation; 2023 Sep; 20(1):215. PubMed ID: 37752582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany.
    Kümpfel T; Thiel S; Meinl I; Ciplea AI; Bayas A; Hoffmann F; Hofstadt-van Oy U; Hoshi M; Kluge J; Ringelstein M; Aktas O; Stoppe M; Walter A; Weber MS; Ayzenberg I; Hellwig K
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33334856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
    Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
    Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.
    Cao S; Wang X; Ji X; Tian J; Zhu Y; Wang X; Gu Y; Duan X; Xiao X; Fang Q; Zhang X; Xue Q
    Mult Scler Relat Disord; 2023 Feb; 70():104524. PubMed ID: 36701910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
    Toorop AA; Hogenboom L; Bloem K; Kocyigit M; Commandeur NWM; Wijnants A; Lissenberg-Witte BI; Strijbis EMM; Uitdehaag BMJ; Rispens T; Killestein J; van Kempen ZLE
    J Neurol Neurosurg Psychiatry; 2023 Jun; 94(6):487-493. PubMed ID: 36693720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
    Baker D; Pryce G; James LK; Marta M; Schmierer K
    Mult Scler Relat Disord; 2020 Sep; 44():102279. PubMed ID: 32645640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.